Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease (DANCE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Mercator MedSystems, Inc. Identifier:
First received: November 4, 2013
Last updated: March 21, 2017
Last verified: March 2017

To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries.

Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.

Condition Intervention Phase
Peripheral Arterial Diseases
Drug: Dexamethasone Sodium Phosphate Injection, USP
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Resource links provided by NLM:

Further study details as provided by Mercator MedSystems, Inc.:

Primary Outcome Measures:
  • MALE-POD [ Time Frame: 30 days ]
    Acute safety safety outcomes will be determined by evaluating the type, frequency, severity, and relatedness of Major Adverse Limb Events or Peri-Operative Death (MALE+POD) within 30 days from the procedure for all subjects.

  • Duplex ultrasound index lesion binary restenosis [ Time Frame: 6 months ]
    Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.

  • Duplex ultrasound index lesion binary restenosis [ Time Frame: 12 months ]
    Binary restenosis will be judged by core laboratory interpretation with peak systolic velocity ratio (PSVR) greater than 2.4.

Secondary Outcome Measures:
  • Long term safety [ Time Frame: 30 days to 6 months ]
    Long term safety outcomes that occur after 30 days through 6 months post-procedure will be determined by evaluating adverse events.

  • Duplex ultrasound index lesion flow limiting restenosis [ Time Frame: 6 and 12 months ]
    Flow limiting restenosis will be judged by core laboratory as PSVR>4.0.

  • Change in inflammatory biomarkers [ Time Frame: Baseline and 24 hours ]
    Change in inflammatory biomarkers will be measured with a panel of biomarkers in 1/3 of patients.

  • Vascular patency [ Time Frame: 6, 12, 18 and 24 months ]
    Target lesion revascularization (TLR) rate, target extremity revascularization (TER) rate, limb salvage rate and primary patency (PSVR≤2.4 and no TLR) at 6, 12, 18 and 24 months. Note: provisional stenting performed during the index procedure shall not be considered to be TLR, TER or loss of primary patency.

  • Clinical outcome measures [ Time Frame: 1, 6, 12, 18 and 24 months ]
    Modified Walking Impairment Questionnaire, Ankle-Brachial Index, Rutherford Score.

  • Infusion Technical Success [ Time Frame: Intraprocedural ]
    Distribution grade around infusion sites.

  • Procedural Success [ Time Frame: Intraprocedural ]
    Establishment of antegrade flow with residual stenosis of <30% by angiogram.

  • Healthcare Economics [ Time Frame: 30 days ]
    Number of return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions within 30 days will be measured.

Enrollment: 285
Study Start Date: November 2013
Estimated Study Completion Date: December 2017
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Adventitial Dexamethasone
In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
Drug: Dexamethasone Sodium Phosphate Injection, USP
Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.

Detailed Description:
This trial will examine the ability for adventitial dexamethasone to safely delay restenosis in patients at least 18 years of age, who have peripheral atherosclerotic lesions involving the superficial femoral and/or popliteal arteries. These patients have no current therapeutic alternatives beyond the procedure used to open, or revascularize, their superficial femoral and/or popliteal arteries. Metal stents have the potential to fracture when implanted in this artery segment due to continual flexion and bending of the knee. It is desirable to improve the patency of this artery after percutaneous transluminal angioplasty (PTA) and/or atherectomy-based revascularization.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Screening Criteria

    • Male or non-pregnant female ≥18 years of age
    • Rutherford Clinical Category 2-4
    • Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb
    • Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen
  • Procedural Criteria

    • De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
    • >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
    • Reference vessel diameter ≥3mm and ≤ 8mm
    • Successful wire crossing of lesion
    • A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)

Exclusion Criteria:

  • Screening Criteria

    • Pregnant, nursing or planning on becoming pregnant in < 2 years
    • Life expectancy of <2 years
    • Known active malignancy
    • History of solid organ transplantation
    • Patient actively participating in another investigational device or drug study
    • History of hemorrhagic stroke within 3 months
    • Previous or planned surgical or interventional procedure within 30 days of index procedure
    • Chronic renal insufficiency with eGFR <29
    • Prior bypass surgery, stenting of the target lesion
    • Inability to take required study medications
    • Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, or Physician prescribed antiplatelet regimen as indicated
    • Systemic fungal infection
    • Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
    • Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
    • Acute limb ischemia
    • Prior participation of the index limb in the current study (contralateral treatment is allowed)
    • Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
    • Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial
  • Procedural Criteria

    • Lesions extending into the trifurcation or above the profunda
    • Heavy eccentric or moderate circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Catheter needle through the vessel wall
    • Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
    • Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
    • Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01983449

  Show 38 Study Locations
Sponsors and Collaborators
Mercator MedSystems, Inc.
Principal Investigator: Mahmood Razavi, MD St. Joseph's Vascular Institute
  More Information

Responsible Party: Mercator MedSystems, Inc. Identifier: NCT01983449     History of Changes
Other Study ID Numbers: TSP0149
1142183 ( Other Identifier: Western IRB )
Study First Received: November 4, 2013
Last Updated: March 21, 2017

Keywords provided by Mercator MedSystems, Inc.:
Peripheral Artery Disease

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 21, 2017